Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

被引：1

作者：

Lavie, David ^{[1
]}

Timmerman, John ^{[2
]}

Garcia-Sanz, Ramon ^{[3
]}

Kim, Won Seog ^{[4
]}

Kim, Tae Min ^{[5
]}

Avigdor, Abraham ^{[6
]}

Dierickx, Daan ^{[7
]}

Jagadeesh, Deepa ^{[8
]}

Molin, Daniel L. ^{[9
]}

Ozcan, Muhit ^{[10
]}

Sevindik, Omur Gokmen ^{[11
]}

Saeed, Hayder ^{[12
]}

Sidi, Yulia ^{[13
]}

Pillai, Pallavi ^{[13
]}

Marinello, Patricia ^{[13
]}

Herrera, Alex F. ^{[14
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[9] Uppsala Univ, Uppsala, Sweden

[10] Ankara Univ, Sch Med, Hematol Dept, Ankara, Turkiye

[11] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Merck & Co Inc, Rahway, NJ 07065 USA

[14] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Lavie, David
Timmerman, John
Sanz, Ramon Garcia
Kim, Won Seog
Kim, Tae Min
Avigdor, Abraham
Dierickx, Daan
Jagadeesh, Deepa
Molin, Daniel
Ozcan, Muhit
Sevindik, Omur Gokmen
Saeed, Hayder
Sidi, Yulia
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth P.
Herrera, Alex F.
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Timmerman, John
BLOOD, 2023, 142
[3] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Tsoran-Rosenthal, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Nahar, Akash
Herrera, Alex F.
BLOOD, 2022, 140
[4] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth
Keane, Colm
Inna, Tzoran
Vucinic, Vladan
Zinzani, Pier Luigi
Zhang, Hong
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth P.
Herrera, Alex F.
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Nahar, Akash
Timmerman, John
BLOOD, 2022, 140 : 6540 - 6542
[6] Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Tzoran, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex F.
BLOOD, 2023, 142
[7] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth
Herrera, Alex Francisco
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Marinello, Patricia
Timmerman, John
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] lTumor Microenvironment in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma before and after Anti-PD-1 Therapy
Gusak, Artem A.
Lepik, Kirill V.
Mikhailova, Natalia B.
Kondakova, Elena
Zalaylov, Yuri R.
Popova, Marina O.
Ionova, Tatiana I.
Kulagin, Aleksandr D.
Afanasyev, Boris V.
Baykov, Vadim
BLOOD, 2020, 136
[9] A phase 1/2 study of favezelimab in combination with pembrolizumab for anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis
Timmerman, John
Lavie, David
Peter, Borchmann
Gregory, Gareth P.
Herrera, Alex Francisco
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Johnson, Nathalie A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
Weiping Liu
Ningjing Lin
Xinqin Feng
Yan Xie
Chong You
Xiaohua Zhou
Yuqin Song
Jun Zhu
Signal Transduction and Targeted Therapy, 8

← 1 2 3 4 5 →